ReviewFrontiers in cell and developmental biology2025
Protein lactylation in kidney diseases.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Lactate in acute kidney injury: pathobiology, risk stratification, and clinical interpretation.Renal failure · 2026Review
- The Lactate-lactylation circuitry in kidney fibrosis: cellular crosstalk from tubular metabolic reprogramming to macrophage effector functions.Seminars in immunopathology · 2026Review
- Article
- Unveiling lactylation: A novel frontier in the pathogenesis of diabetic nephropathy (Review).International journal of molecular medicine · 2026Review
- Lactylation in sepsis-associated acute kidney injury: regulatory mechanisms and therapeutic prospects.Frontiers in molecular biosciences · 2026Review
- Protein lactylation in myocardial ischemia-reperfusion injury: mechanisms and therapeutic potential.Frontiers in cardiovascular medicine · 2026Review
- Lactate Metabolism and Protein Lactylation in Diabetic Kidney Disease: A Narrative Review.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-translational modifications (PTMs) regulate protein function and structure through covalent modifications, participating in various physiological and pathological processes. Lysine lactylation is an emerging PTM discovered in recent years, which regulates gene expression, metabolism, and cell signaling by adding a lactyl group to lysine residues. As a by-product of glycolysis, lactate not only influences cellular metabolism but also contributes to the development and progression of kidney diseases through lactylation. This review focuses on the discovery and regulatory mechanisms of lysine lactylation, particularly its role in kidney diseases such as acute kidney injury, chronic kidney disease, and diabetic kidney disease. Lactylation influences the metabolic state, inflammatory response, and fibrosis of renal cells by modulating protein function and key gene transcription. With continued research, lactylation is expected to become a novel target for understanding the metabolic-epigenetic regulation of kidney diseases and could offer new strategies for treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.